Antares Pharma, Inc. (NASDAQ:ATRS) Expected to Announce Quarterly Sales of $44.01 Million

Equities analysts expect that Antares Pharma, Inc. (NASDAQ:ATRSGet Rating) will report sales of $44.01 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Antares Pharma’s earnings, with estimates ranging from $41.70 million to $45.06 million. Antares Pharma posted sales of $42.08 million in the same quarter last year, which suggests a positive year-over-year growth rate of 4.6%. The company is expected to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Antares Pharma will report full-year sales of $211.76 million for the current fiscal year, with estimates ranging from $209.10 million to $214.10 million. For the next year, analysts expect that the business will report sales of $260.86 million, with estimates ranging from $245.04 million to $282.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Antares Pharma.

Antares Pharma (NASDAQ:ATRSGet Rating) last released its quarterly earnings data on Thursday, March 3rd. The specialty pharmaceutical company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01. Antares Pharma had a net margin of 25.16% and a return on equity of 12.33%. The company had revenue of $48.73 million during the quarter, compared to analyst estimates of $46.25 million. During the same period last year, the business earned $0.03 earnings per share.

ATRS has been the topic of several analyst reports. LADENBURG THALM/SH SH downgraded shares of Antares Pharma from a “buy” rating to a “neutral” rating in a research note on Thursday, April 14th. HC Wainwright downgraded shares of Antares Pharma from a “buy” rating to a “neutral” rating and set a $5.60 target price on the stock. in a research note on Thursday, April 14th. Truist Financial downgraded shares of Antares Pharma from a “buy” rating to a “hold” rating and reduced their price objective for the company from $7.00 to $5.60 in a research report on Wednesday, April 13th. Piper Sandler downgraded shares of Antares Pharma from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $6.00 to $5.60 in a research report on Thursday, April 14th. Finally, Zacks Investment Research raised shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a research report on Wednesday, May 4th. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $5.76.

Shares of ATRS stock traded up $0.01 during trading hours on Friday, hitting $5.57. 7,110,907 shares of the company’s stock were exchanged, compared to its average volume of 3,398,715. The company has a market capitalization of $951.26 million, a PE ratio of 20.63 and a beta of 1.15. Antares Pharma has a 12-month low of $3.11 and a 12-month high of $5.59. The business’s 50 day simple moving average is $4.62 and its 200-day simple moving average is $3.88. The company has a current ratio of 2.96, a quick ratio of 2.76 and a debt-to-equity ratio of 0.10.

Hedge funds have recently made changes to their positions in the company. Panagora Asset Management Inc. lifted its stake in Antares Pharma by 8.8% during the 1st quarter. Panagora Asset Management Inc. now owns 916,896 shares of the specialty pharmaceutical company’s stock valued at $3,759,000 after acquiring an additional 74,286 shares during the period. MetLife Investment Management LLC increased its position in shares of Antares Pharma by 131.1% during the 1st quarter. MetLife Investment Management LLC now owns 84,197 shares of the specialty pharmaceutical company’s stock valued at $345,000 after purchasing an additional 47,767 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Antares Pharma by 2.4% during the 1st quarter. Bank of New York Mellon Corp now owns 736,241 shares of the specialty pharmaceutical company’s stock valued at $3,019,000 after purchasing an additional 17,151 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Antares Pharma during the 1st quarter valued at about $58,000. Finally, Boston Partners increased its position in shares of Antares Pharma by 137.8% during the 1st quarter. Boston Partners now owns 420,620 shares of the specialty pharmaceutical company’s stock valued at $1,725,000 after purchasing an additional 243,758 shares during the last quarter. Hedge funds and other institutional investors own 50.41% of the company’s stock.

About Antares Pharma (Get Rating)

Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems.

Recommended Stories

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.